GO
Loading...

Johnson & Johnson

More

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall. Shares of Sunnyvale, California- based Pharmacyclics Inc. jumped in premarket trading Thursday while AbbVie Inc. shares fell. AbbVie will offer a mix of cash and stock to Pharmacyclics...

  • March 4- Johnson& Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter. Bloomberg reported last month, citing sources, that...

  • Report: J&J close to deal to buy partner Pharmacyclics Wednesday, 4 Mar 2015 | 6:24 PM ET

    Health care giant Johnson& Johnson reportedly is close to buying biopharmaceutical company Pharmacyclics, its longtime partner in developing blood cancer treatment Imbruvica. London's Financial Times reports "people familiar with the matter" say Johnson& Johnson's anticipated offer would value Pharmacyclics of Sunnyvale, California, above its current...

  • Final Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 6:17 PM ET

    Baxter International Inc. fell$. 17 or. 2 percent, to $69.25. Bristol-Myers Squibb Co. rose $3.75 or 6.1 percent, to $65.67. Eli Lilly& Co. rose$. 28 or. 4 percent, to $70.65.

  • Final Glance: Medical Devices companies Wednesday, 4 Mar 2015 | 6:17 PM ET

    Allergan rose$. 82 or. 3 percent, to $235.68. Baxter International Inc. fell$. 17 or. 2 percent, to $69.25. Boston Scientific Corp. rose$. 03 or. 2 percent, to $16.79.

  • Midday Glance: Medical Devices companies Wednesday, 4 Mar 2015 | 1:16 PM ET

    Allergan rose$. 18 or. 1 percent, to $235.04. Baxter International Inc. rose$. 11 or. 2 percent, to $69.53. Boston Scientific Corp. rose$. 06 or. 3 percent, to $16.82.

  • Midday Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 1:16 PM ET

    Baxter International Inc. rose$. 11 or. 2 percent, to $69.53. Bristol-Myers Squibb Co. rose$. 86 or 1.4 percent, to $62.78. Eli Lilly& Co. rose$. 16 or. 2 percent, to $70.53.

  • Early Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 10:36 AM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $69.14. Bristol-Myers Squibb Co. fell$. 40 or. 6 percent, to $61.52. Eli Lilly& Co. fell$. 43 or. 6 percent, to $69.94.

  • Early Glance: Medical Devices companies Wednesday, 4 Mar 2015 | 10:36 AM ET

    Allergan fell$. 22 or. 1 percent, to $234.64. Baxter International Inc. fell$. 28 or. 4 percent, to $69.14. Boston Scientific Corp. rose$. 02 or. 1 percent, to $16.78.

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • Final Glance: Pharmaceuticals companies Tuesday, 3 Mar 2015 | 6:05 PM ET

    Baxter International Inc. fell$. 54 or. 8 percent, to $69.42. Bristol-Myers Squibb Co. fell$. 38 or. 6 percent, to $61.92. Eli Lilly& Co. fell$. 75 or 1.1 percent, to $70.37.

  • Final Glance: Medical Devices companies Tuesday, 3 Mar 2015 | 6:05 PM ET

    Allergan fell$. 94 or. 4 percent, to $234.86. Baxter International Inc. fell$. 54 or. 8 percent, to $69.42. Boston Scientific Corp. fell$. 30 or 1.8 percent, to $16.76.

  • Cramer: Market headed for froth—time to sell? Monday, 2 Mar 2015 | 6:12 PM ET

    Jim Cramer sees a perfect recipe of market froth happening. Is now the time to sell your stocks?

  • Final Glance: Pharmaceuticals companies Monday, 2 Mar 2015 | 6:08 PM ET

    Baxter International Inc. rose$. 81 or 1.2 percent, to $69.96. Bristol-Myers Squibb Co. rose $1.38 or 2.3 percent, to $62.30. Eli Lilly& Co. rose$. 95 or 1.4 percent, to $71.12.

  • Final Glance: Medical Devices companies Monday, 2 Mar 2015 | 6:08 PM ET

    Allergan rose $3.06 or 1.3 percent, to $235.80. Baxter International Inc. rose$. 81 or 1.2 percent, to $69.96. Boston Scientific Corp. rose$. 16 or. 9 percent, to $17.06.

  • Biotech drugmaker Amgen Inc.' s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Amgen, based in Thousand Oaks, California, on Sunday released interim results from its study. The Amgen- funded study, known by the acronym ENDEAVOR, included 929 patients who had relapsed after...

  • Midday Glance: Medical Devices companies Monday, 2 Mar 2015 | 1:17 PM ET

    Allergan rose $2.13 or. 9 percent, to $234.87. Baxter International Inc. rose$. 62 or. 9 percent, to $69.77. Boston Scientific Corp. rose$. 13 or. 8 percent, to $17.03.

  • *Markit manufacturing hits 4- month high, ISM hits 13- month low. NEW YORK, March 2- U.S. stocks advanced on Monday to push the Nasdaq above the 5,000 mark for the first time in fifteen years, as a round of mixed data pointed to a slowly accelerating economy. "Five thousand on the Nasdaq, it's been a long time coming," said Peter Kenny, chief market strategist at Clearpool...